Hostname: page-component-74656f9884-6grmk Total loading time: 0 Render date: 2026-11-06T09:10:10.318Z Has data issue: false hasContentIssue false

Social fears and social phobia in the USA: results from the National Comorbidity Survey Replication

Published online by Cambridge University Press:  02 November 2007

A. M. Ruscio*
Affiliation:
Department of Psychology, University of Pennsylvania, Philadelphia, PA, USA
T. A. Brown
Affiliation:
Department of Psychology, Boston University, Boston, MA, USA
W. T. Chiu
Affiliation:
Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
J. Sareen
Affiliation:
Department of Psychiatry and Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
M. B. Stein
Affiliation:
Department of Psychiatry, University of California, San Diego, CA, USA
R. C. Kessler
Affiliation:
Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
*
*Address for correspondence: Dr A. M. Ruscio, Department of Psychology, University of Pennsylvania, 3720 Walnut Street, Philadelphia, PA 19104, USA. (Email: ruscio@psych.upenn.edu)
Rights & Permissions [Opens in a new window]

Abstract

Background

Despite heightened awareness of the clinical significance of social phobia, information is still lacking about putative subtypes, functional impairment, and treatment-seeking. New epidemiologic data on these topics are presented from the National Comorbidity Survey Replication (NCS-R).

Method

The NCS-R is a nationally representative household survey fielded in 2001–2003. The World Health Organization (WHO) Composite International Diagnostic Interview Version 3.0 (CIDI 3.0) was used to assess 14 performance and interactional fears and DSM-IV social phobia.

Results

The estimated lifetime and 12-month prevalence of social phobia are 12.1% and 7.1% respectively. Performance and interactional fears load onto a single latent factor, and there is little evidence for distinct subtypes based either on the content or the number of fears. Social phobia is associated with significant psychiatric co-morbidity, role impairment, and treatment-seeking, all of which have a dose–response relationship with number of social fears. However, social phobia is the focus of clinical attention in only about half of cases where treatment is obtained. Among non-co-morbid cases, those with the most fears were least likely to receive social phobia treatment.

Conclusions

Social phobia is a common, under-treated disorder that leads to significant functional impairment. Increasing numbers of social fears are associated with increasingly severe manifestations of the disorder.

Information

Type
Original Articles
Copyright
Copyright © Cambridge University Press 2007
Figure 0

Table 1. Lifetime prevalence of social fears and DSM-IV social phobia (n=9282)

Figure 1

Fig. 1. Age of onset of first social fear in four mutually exclusive social phobia subgroups involving different numbers of social fears. Cumulative age-of-onset distributions were estimated in the subsample of respondents with lifetime social phobia. The distributions differ significantly across the four social phobia subgroups (χ32=27.4, p<0.001).

Figure 2

Table 2. Lifetime co-morbidity (OR)a of social phobia and four mutually exclusive social phobia subgroups with other DSM-IV disorders

Figure 3

Table 3. Role impairmenta in 12-month social phobia and four mutually exclusive social phobia subgroups

Figure 4

Table 4. Lifetime and 12-month treatmenta of social phobia and four mutually exclusive social phobia subgroups